uploads/2018/07/Chart-04-4-1.jpg

LLY’s Cardiovascular Products: Cialis and Effient Q2 Sales Fall

By

Updated

Cardiovascular product portfolio

Eli Lilly & Co.’s (LLY) Human Pharmaceuticals business includes cardiovascular products such as Effient and Cialis. Cialis and Effient reported lower sales during the second quarter, compared to the second quarter of 2017. The chart below shows revenues for LLY’s cardiovascular products since the first quarter of 2017.

Article continues below advertisement

Cialis

Cialis, a blockbuster drug from Eli Lilly’s portfolio, is approved for the treatment of erectile dysfunction and benign prostatic hyperplasia. Cialis reported revenues of $538.7 million during the second quarter, a 14.0% YoY (year-over-year) decrease compared to $627.3 million during the second quarter of 2017. 

This decline was driven by the lower sales of Cialis in its US and international markets. The drug’s US sales fell 9.0% to $345.7 million, and its international markets reported a 22.0% decrease in sales to $193.0 million during the quarter.

Effient

Effient, an antiplatelet drug for the prevention of blood clots in arteries and stents, is approved for use in combination with aspirin. The drug is part of Eli Lilly’s collaboration with Daiichi Sankyo, and Eli Lilly holds the marketing rights for the US markets. Daiichi Sankyo holds the marketing rights for its European markets and Japan.

Effient reported revenues of $27.9 million during the second quarter, a YoY decline compared to revenues of $142.9 million during the second quarter of 2017.

Other drugs

Adcirca, Zalutia, and Livalo are other cardiovascular products from Eli Lilly. The revenues for the company’s other drugs totaled $126.4 million during the second quarter, driven by strong growth in the US sales. These revenues were partially offset by lower sales from the international markets.

The iShares US Pharmaceuticals ETF (IHE) holds 6.5% of its portfolio in Eli Lilly (LLY), 8.7% in Pfizer (PFE), 8.0% in Merck & Co. (MRK), and 6.6% in Bristol-Myers Squibb (BMY).

Advertisement

More From Market Realist